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Abstract
Background: Smoking is a major preventable cause of morbidity and premature death worldwide. Both varenicline
and nicotine replacement therapy (NRT) help achieve smoking cessation. However, limited evidence exists regarding
whether combination of varenicline and NRT is more effective than either alone. The aim of this research was to
investigate the efficacy and safety of varenicline combined with NRT.
Methods: A systematic search of MEDLINE, EMBASE, ClinicalTrial.gov, and Cochrane Library was conducted in
November 2014. Two authors independently reviewed and selected randomized controlled trials. The quality of
the studies was evaluated by the Jadad score. We carried out meta-analysis of both early (abstinence rate
assessed before or at the end of treatment) and late (assessed after the end of the treatment) outcomes.
Results: Three randomized controlled trials with 904 participants were included in this meta-analysis. All three
were comparing combination therapy with varenicline therapy alone. The late outcomes were assessed in 2 of
the 3 trials. Both the early and late outcomes were favorable for combination therapy (OR = 1.50, 95 % CI 1.14 to
1.97; OR = 1.62, 95 % CI 1.18 to 2.23, respectively). However, this significance diminished after eliminating a study
with pre-cessation treatment using nicotine patch. The most common adverse events were nausea, insomnia,
abnormal dreams, and headache. One study reported more skin reactions (14.4 % vs 7.8 %; p = 0.03) associated
with combination therapy.
Conclusions: Combination therapy is more effective than varenicline alone, especially if pre-cessation treatment
of nicotine patch is administrated. Adverse events of combination therapy are similar to mono-therapy except for
skin reactions.
Keywords: Smoking cessation, Combination therapy, Varenicline, Nicotine replacement therapy, Systematic
review, Meta-analysis
Background
Smoking is a leading preventable cause of morbidity and
premature death worldwide [1]. It has been well estab-
lished that smoking increases risk of respiratory disease,
cardiovascular disease, diabetes mellitus, autoimmune
disorders, reproductive system disorders, and many
kinds of cancers [2]. Varenicline not only acts as a partial
agonist to attenuate withdrawal symptoms during smok-
ing cessation, but also as an agent to block nicotine
binding [3]. In a guideline proposed to treat tobacco use
and dependence in 2008, seven first-line medications
were recommended (nicotine in the forms of gum, in-
haler, lozenge, nasal spray and patch, sustained release
bupropion hydrochloride, and varenicline) [4]. Among
them, varenicline had the highest abstinence rate. A
meta-analysis revealed that varenicline was more effect-
ive than standard-dose nicotine replacement therapy
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(NRT) (relative risk = 1.38, 95 % CI 1.15 to 1.64 at
6 months), but was similar to high-dose NRT (relative
risk = 1.05, 95 % CI 0.80 to 1.36 at 6 months) [5]. In another
meta-analysis, although varenicline was still regarded as the
most effective mono-therapy, it was not superior to com-
bination therapy of two different types of NRT [odds ratio
(OR) = 1.06, 95 % CI 0.75 to 1.48] [6].
Combination therapy of varenicline with other medi-
cations was not recommended in the guideline proposed
by the National Institute for Health and Care Excellence
(NICE) [7]. Combination therapy of varenicline with
NRT is not recommended either by the US Public
Health Clinical Practice Guideline for Treating Tobacco
Use and Dependence [4]. The efficacy of combination
therapy was inconsistent. A retrospective study revealed
that the combination therapy of varenicline and NRT
was tolerable, but was not superior to mono-therapy [8].
One randomized controlled trial (RCT) showed that vare-
nicline combined with nicotine patch was more effective
than varenicline alone to achieve continuous abstinence
rate at 12 and 24 weeks [9]. However, another two RCTs
showed no superior effects [10, 11]. This research aimed
to evaluate the efficacy and safety of varenicline combined




We conducted a comprehensive search in November
2014. The databases included MEDLINE (from 1966 to
November 2014), EMBASE (from 1966 to November
2014), ClinicalTrail.gov (from 2000 to November 2014)
and the Cochrane Library. Search terms were vareni-
cline, nicotine replacement therapy (including nicotine
patch, gum, inhaler, nasal spray, lozenge). We combined
“varenicline” and “nicotine replacement therapy” by the
Boolean operator “and” for screening in titles, abstracts and
key words. Then the results were limited to “randomized
controlled trial”. After selecting articles, we searched the
reference lists for relevant citations. We limited the
language to English. We did not limit countries of
publications.
Selection criteria
Only published RCTs with an adult population were in-
cluded. Trials had to investigate combination treatment
of varenicline and nicotine replacement therapy. The re-
quired outcomes were abstinence rates with biochemical
verification, safety profile, or tolerability of the therapy.
Exclusion criteria included non-RCT studies, trials with-
out outcome measurements, trials using smoking cessa-
tion medications but not aiming to stop cigarette
smoking (eg. stop alcohol use or long term NRT use),
and articles that the full-text was not available.
Study selection
One author (WC) searched the electronic databases. The
results were independently assessed by two authors (WC
and PZ). The authors identified articles eligible for fur-
ther review by screening the titles and abstracts. The
second step of selection was based on the full-text of ar-
ticles. The disagreements were resolved by consensus
between authors. A standardized data extraction form
was used to collect population characteristics, study in-
clusion and exclusion criteria, intervention details, and
outcome data from each study.
Data extraction
Information was extracted from each included trial on:
(1) characteristics of trial participants (including age,
sex, location, Fagerström Test for Nicotine Dependence
(FTND) score), and the trial’s inclusion and exclusion
criteria; (2) type of intervention (including type, dose,
duration and frequency of varenicline and NRT; behav-
ioral counseling); (3) type of outcome measure (exhaled
carbon monoxide, self-reporting), length of follow-up,
adverse effects. One author (WC) extracted the data from
included studies and the second author (PZ) checked
the extracted data. Disagreements were resolved by dis-
cussion between the two review authors; if no agreement
could be reached, it was planned a third author (PH)
would decide.
Quality assessment and publication bias
The quality of the studies was assessed by the Jadad score
[12]. The score ranges from 0 to 5 according to
randomization, blinding, and patient dropout. We assessed
the risk of publication bias by funnel plots. Asymmetry in a
funnel plot was considered as a risk of publication bias. We
used Begg’s rank correlation test and Egger’s regression test
for statistical verification of bias [13]. The test results were
generated by Comprehensive Meta-Analysis Version 2 soft-
ware (Biostat, Englewood, NJ, USA).
Statistical analysis
Pooled ORs were used to compare the effects of treat-
ments. We defined the early outcome as the quit rate
assessed before or at the end of treatment completion.
The late outcome was the quit rate assessed for a period
of time after the end of treatment completion, majorly at
24 or more weeks. The case numbers of adverse events
were aggregated and the event rates were expressed as
percentages. We calculated the ORs and 95 % confi-
dence intervals (95 % CI) of adverse events by fixed ef-
fect model. Between-study heterogeneity was estimated
using the χ2-based Q statistic [14] and heterogeneity was
considered statistically significant when P-value was less
than 0.1. If heterogeneity was significant, the pooled esti-
mate was calculated based on the random effects model
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[15]. In the absence of significant heterogeneity, the
pooled estimate was calculated using the fixed effect
model [16]. A statistical test with a P value less than 0.05
was considered significant in pooled estimates. The forest
plots and pooled estimates were generated by Review
Manager (RevMan Version 5.3 Copenhagen: The Nordic
Cochrane Centre, The Cochrane Collaboration, 2014).
Results
Study identification
The search strategy retrieved a total of 63 citations. Of
these, three were appropriate for full-text review (Fig. 1).
No additional study was identified after searching the refer-
ence lists of these three articles. After review, all three stud-
ies [9–11] were finally included in the systematic review
and meta-analysis (Table 1). These three studies were all
combination therapy versus varenicline alone therapy trials.
Characteristics of included studies
Table 1 summarizes the baseline demographics, number
of participants, interventions, and outcome measurements
of included studies. All three trials recruited smokers who
were aged 18 and over, not breastfeeding or pregnant, and
had no current psychiatric or other serious illness. The in-
clusion and exclusion criteria were well described in two
studies [9, 11], requiring that the enrolled patients have no
recent experience of other cessation medication or suc-
cessful abstinence. The other study provided relatively
simple criteria that volunteers seeking treatment with no
contraindications could be enrolled [10]. The mean age of
participants was similar among all studies. One study in-
cluded more female subjects than males [9]. There were
38.3 % males in this study vs 66.7 and 57.8 % in the other
two studies respectively. The Fagerström Test for Nicotine
Dependence (FTND) score was higher in one study be-
cause it included smokers who smoked 20 or more ciga-
rettes per day [11], whereas the other two studies included
participants with lower daily cigarettes consumption.
Treatment interventions differed among these studies.
One study administered trial patch two weeks before the
TQD, while the other two studies started patch use on the
TQD. Two studies used a 15 mg/16 hours patch, while
Fig. 1 Flow diagram of meta-analysis: inclusion and exclusion of studies
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the other [11] used a 21 mg/24 hours patch. On the
other hand, the use of varenicline was similar among
the studies. All started at 0.5 mg per day one week be-
fore TQD, with increase to 2 mg/day on TQD, and
continued for 12 weeks. One study [9] tapered the
dose of varenicline on the 13th week. All studies pro-
vided concurrent behavioral counseling during the
treatment phase. One study [10] measured the early
outcome at 4 weeks; the other two measured it at
12 weeks. All studies used exhaled carbon monoxide
to confirm continuous abstinence. For the late out-
come, one study [9] measured 9 to 24 weeks of con-
tinuous abstinence, one [11] measured 2 to 24 weeks
of continuous abstinence, and the other one did not
measure outcome after treatment phase. One study
[10] measured self-reported point prevalence at 12 weeks,
which was not included in our meta-analysis. All studies
adopted our definition of early outcome as the primary
outcome, while our defined late outcome as the secondary
outcome.
Study quality and publication bias
The Jadad score of included studies ranged from 4 to 5.
Only one study was granted a score of 4 because the
dropout of patients was not detailed in the article [10].
The overall quality of the included studies was high. The
funnel plot of early outcome was not symmetrical due to
lack of smaller studies with positive effect. However, the
power of the funnel plot was compromised by the small
number of studies. The publication bias assessed by
Begg’s rank correlation test and Egger’s regression test
was not significant (p = 0.30 and 0.28 respectively). The
publication bias of late outcome was not assessed be-
cause there were only two studies included. The Com-
prehensive Meta-Analysis software could not generate a
funnel plot or a test report under this situation.
Varenicline plus nicotine patch versus varenicline plus
placebo patch: the early outcome
Three studies with a total of 904 participants were in-
cluded in this meta-analysis (Fig. 2). The heterogeneity
Table 1 Baseline characteristics of the included studies
Source Participants Mean age Male % FTNDa Location Jadad score Intervention Early outcome Late outcome
Hajek [10] Active: 58 44.5 66.7 % 4.9 London, UK,
1 center
4 15 mg/16 hours nicotine patch,






Placebo: 59 Varenicline 1 week before TQD,
titrated to 2 mg/day, continued
to 12th weekTotal: 117
Koegelenberg [9] Active: 216 46.3 38.3 % 4.5 South Africa,
7 centers
5 15 mg/16 hours nicotine patch,
started 2 weeks before TQD,







Placebo:219 Varenicline 1 week before TQD,
titrated to 2 mg/day, continued
to 12th week, tapered on the
13th week
Total: 435
Ramon [11] Active: 170 45.2 57.8 % 6.5 Barcelona,
Spain,
1 center
5 21 mg/24 hours nicotine patch,








Placebo:171 Varenicline 1 week before TQD,
titrated to 2 mg/day, continued
to 12th weekTotal: 341
FTND, Fagerström Test for Nicotine Dependence; TQD, target quit date
aranging from 0 to 10, a higher score denotes greater dependence
Fig. 2 Varenicline plus nicotine patch vs varenicline plus placebo patch: the early outcome
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was minimal (I2 = 0 %, p = 0.41), therefore fixed effect
model was used. The results demonstrated a significant
increase in abstinence rate (44.4 % vs 35.1 %, OR = 1.50,
95 % CI 1.14 to 1.97). All three studies showed a favor-
able effect of combination therapy, while only one of
them reached statistical significance [9].
Varenicline plus nicotine patch versus varenicline plus
placebo patch: the late outcome
Two studies with a total of 787 participants were in-
cluded in this meta-analysis (Fig. 3). The heterogeneity
was moderate (I2 = 54 %) without statistical significance
(p = 0.14). The fixed effect model was also used. The re-
sults demonstrated a significant increase in abstinence
rate (32.4 % vs 23.1 %, OR = 1.62, 95 % CI 1.18 to 2.23).
Both studies showed a favorable effect of combination
therapy, while only one of them reached statistical sig-
nificance [9].
The safety of combination therapy
The case numbers of adverse events were aggregated.
The pooled ORs were generated by fixed effect model
(Table 2). Combination therapy reported more nausea
(28.4 % vs 25.7 %), insomnia (18.7 % vs 15.4 %), abnormal
dreams (13.6 % vs 10.7 %), but less headache (7.1 % vs
7.8 %). There were no significant differences between
nicotine and placebo patch groups. Only one study re-
ported the adverse events of depression, especially in the
nicotine patch group (2.3 % vs 1.4 %; p = 0.50) [9]. This
study also reported more skin reactions in the nicotine
patch group (14.4 % vs 7.8 %; p = 0.03).
A total of eight serious adverse events (SAEs) were re-
ported in the included studies, where only one of them
was considered relevant to the study medications. This
was a female participant who became pregnant during
the treatment phase where she was randomized to re-
ceive placebo patch combined with varenicline. She later
on gave birth to an infant with Down syndrome and
congenital heart defects. Another SAE was a female par-
ticipant who also became pregnant during treatment
phase with placebo patch. She had an anembryonic preg-
nancy and this SAE was considered to be irrelevant to
the study medications.
Subgroup and sensitivity analysis
We did not perform subgroup analysis because of the
small number of studies, and there was no significant
heterogeneity. One RCT was identified to be different in
study design (pre-cessation treatment with patch) and
participant characteristics (more females than males) [9].
When we eliminated this RCT from the meta-analysis
model of the early outcome, the favorable effect of com-
bination therapy became insignificant (OR = 1.28, 95 % CI
0.87 to 1.87). We then preformed sensitivity analysis of
the late outcome in the same manner and the favorable ef-
fect of combination therapy also diminished (OR = 1.26,
95 % CI 0.79 to 2.00). We compared the results of fixed ef-
fect to random effects model of both early and late out-
comes. The OR was 1.50 (95 % CI 1.14 to 1.97) vs 1.50
(95 % CI 1.14 to 1.97) in the early outcomes, 1.62 (95 % CI
1.18 to 2.23) vs 1.61 (95 % CI 1.00 to 2.58) in the late out-
comes respectively. The conclusion of favorable effect per-
sisted even using different models.
Discussions
Our research identified three smoking cessation trials
comparing varenicline combined with nicotine patch
versus varenicline combined with placebo patch. No
other types of nicotine product were combined with var-
enicline in these trials. We found no trials comparing
combination therapy with NRT alone that met our inclu-
sion and exclusion criteria. One RCT that compared
combination therapy and NRT was not included because
it combined varenicline and counseling to get long-term
NRT users to quit NRT [17]. After meta-analysis, our re-
sults demonstrated favorable effects of combination
therapy in both early and late outcomes. To our
Fig. 3 Varenicline plus nicotine patch vs varenicline plus placebo patch: the late outcome







Nausea 123 (28.4) 113 (25.7) 1.15 (0.85, 1.56)
Insomnia 83 (18.7) 69 (15.4) 1.27 (0.89, 1.80)
Abnormal
dreams
51 (13.6) 44 (10.7) 1.20 (0.78, 1.84)
Headache 30 (7.1) 30 (7.8) 1.01 (0.60, 1.72)
aPooled event rates and odds ratios calculated by fixed effect model
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knowledge, this is the first systematic review and meta-
analysis on this issue.
In our main analysis, the early outcomes in varenicline
combined with placebo patch group were consistent
with previous studies using varenicline mono-therapy
(abstinence rate 44.4 % vs 43.9 %) [18]. The late out-
comes were also similar (abstinence rate 32.4 % vs
29.7 %). In sensitivity analysis, we identified the largest
RCT [9] which markedly influenced the results. After
eliminating this RCT, the favorable effects of both early
and late outcomes became insignificant. We identified
two distinguishing factors that might have caused this
difference. First, there were more female subjects in this
RCT. Previous studies have revealed that the effect of
varenicline did not differ among genders [19–21]. On
the other hand, some studies yielded inconsistent reports
on whether male subjects using NRT had higher abstin-
ence rates than females [22–25]. If nicotine patch use
had been less effective in females, the higher percentage
of females in this RCT would bring about less effective
outcomes, which was not the case. Therefore, gender
difference did not seem to contribute to the treatment
effect of this RCT.
Second, this RCT [9] used a pre-cessation nicotine
patch. A meta-analysis conducted by Shiffman S et al.
showed that pre-cessation nicotine patch significantly in-
creased abstinence rates at 6 weeks (OR = 1.96, 95 % CI
1.31 to 2.93) and at 6 months (OR = 2.17, 95 % CI 1.46
to 3.22) [26]. However, this positive effect was not con-
sistent in the following meta-analyses [6, 27, 28]. These
meta-analyses showed that pre-cessation nicotine patch
and gum had a moderate but insignificant increase in
abstinence rates. Pre-cessation nicotine patch appeared
to be more effective than pre-cessation nicotine gum
[27]. Therefore, we favored that the effect of pre-
cessation nicotine patch contributed to the better out-
comes in this RCT.
The rationale of combination therapy of varenicline
with NRT resides in the hypotheses that 1) varenicline
does not fully saturate α4β2 nicotinic acetylcholine re-
ceptors; 2) varenicline does not completely replace the
dopaminergic effect of smoking [29]. A standard-dose of
varenicline (1.0 mg) could achieve higher abstinence
rates than low-dose varenicline (0.5 mg) [3]. Further sat-
uration of the receptors seemed to explain the additive
effect of NRT. However, a neuropharmacological study
utilizing positron emission tomography revealed that a
single dose of 0.5 mg varenicline could saturate α4β2 re-
ceptors in the human brain [30]. It deserves a debate
whether the combination to α4β2 nicotinic acetylcholine
receptors, and subsequent mesolimbic dopamine release is
the only pathway that causes reward in smoking. Nicotine
addiction develops from complex pathways, and individual
genotypes influence both smoking behavior and treatment
effects [31, 32]. The modulation of α4β2 receptors might
not be the only pathway to release dopamine, and dopa-
mine might not be the only neurotransmitter involved in
smoking behavior. More studies are required to explore
the mechanism of combining varenicline with NRT.
The event rates of adverse effects were similar in the
two groups. The only significant increase in adverse
events was skin reactions in one RCT [9]. The event rate
of skin reactions was comparable to those in nicotine
patch mono-therapy [28]. Other adverse events of com-
bination therapy were not higher than findings from pre-
vious studies of varenicline mono-therapy [3]. The birth
of an infant with Down syndrome (trisomy 21) in one
study [9] was considered relevant to varenicline, classi-
fied as a Pregnancy Category C drug. Koegelenberg et al.
considered that the causality was less likely because the as-
sociation was not observed in post-marketing researches
[33, 34]. Varenicline combined with nicotine patch ap-
peared to be safe and tolerable in smoking cessation.
The question of small study number
Critics might argue that it was too early to perform a
meta-analysis when there were only three RCTs avail-
able. Borenstein et al. suggested that it makes sense to
perform a meta-analysis as soon as we have two studies,
since a summary based on two studies yields a more
precise estimate of the true effect than either study alone
[35]. However, the estimate of the pooled effects would
have poor precision. Three solutions are suggested
under such circumstance [36]. One option is to report
the separate effects and not report a summary effect.
Readers are expected to understand that authors cannot
draw conclusions about the effect size. The problem is
that some readers may revert to ‘vote counting’ and pos-
sibly reach an erroneous conclusion. Another option is
to perform a fixed effect analysis. This approach yields a
descriptive analysis of the included studies, but does not
allow us to make inferences about a wider population. A
third option is to take a Bayesian approach, where the
estimate of variance is based on data from outside of the
current studies. We selected the second approach and
used fixed effect model in our analysis.
Strengths and limitations
In our study, we searched the major databases with
rigorous strategies. There were duplicated authors who
selected the articles independently, allowing for a low
probability that an important study was missed. The in-
cluded studies had high quality and the Jadad score
ranged from 4 to 5. The heterogeneity between the se-
lected studies was low, and there were no significant
publication biases. We evaluated both early and late out-
comes which was more comprehensive than short-term
evaluations. However, there were some limitations. We
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did not search grey literature or un-published data. Tri-
als that were less known might have been missed. The
strength of our research was compromised by the small
number of trials. The largest RCT which had the great-
est influence to our results was different from the other
RCTs in demographic characteristics and treatment de-
sign. The impact was that our conclusions could not be
generalized to other populations. Also, the funnel plot
and tests of publication bias had low power to detect a
potential bias. In our review, the adverse events of de-
pression and skin reactions were only reported in one
study. There was no report of cardiovascular or suicidal
events. The safety of combination therapy requires fur-
ther investigations.
Conclusions
The combination therapy of varenicline with NRT is
more effective than varenicline alone in smoking cessa-
tion. This effect is more evident if pre-cessation treat-
ment of nicotine patch is administrated. The adverse
events of combination therapy are comparable to vareni-
cline mono-therapy with the exception of skin reactions.
Larger RCTs are needed to make more robust conclusions.
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